


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (I)



or a salt[,], or ester [~~or prodrug~~] thereof;

where:

X is O or NR⁶;

R⁶ is hydrogen or C₁₋₄alkyl;

R¹ is hydrogen, halo, or -X¹R¹¹;

X¹ is a direct bond, -CH₂=CH₂-, -O-, -NH-, -N(C₁₋₆alkyl)-, -C(O)-, -C(O)O-, -OC(O)-, -NHC(O)-, -N(C₁₋₆alkyl)C(O)-, -C(O)NH or -C(O)N(C₁₋₆alkyl)-;

R¹¹ is hydrogen, or a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, heterocyclyl, heterocyclylC₁₋₄alkyl, heterocyclylC₂₋₄alkenyl and heterocyclylC₂₋₄alkynyl which group is optionally substituted by 1 or 2 substituents independently selected from halo, hydroxy, C₁₋₄alkoxy, hydroxyC₁₋₄alkyl, -NR⁹R¹⁰, -C(O)R⁹, -C(O)NR⁹R¹⁰ and -C(O)OR⁹;

R² is hydrogen, halo, nitro, cyano or -X²R¹²;

X² is a direct bond, -O-, -NH-, -N(C₁₋₆alkyl)-, -OC(O)- or -C(O)O-;

R¹² is hydrogen, or a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, aryl, arylC₁₋₄alkyl, arylC₂₋₄alkenyl, arylC₂₋₄alkynyl, heterocyclyl, heterocyclylC₁₋₄alkyl, heterocyclylC₂₋₄alkenyl and heterocyclylC₂₋₄alkynyl, which group is optionally substituted by 1, 2 or 3 substituents independently selected from, halo, hydroxy, C₁₋₄alkyl, C₁₋₄alkoxy, -NR¹⁵R¹⁶, -NHC(O)NR¹⁵R¹⁶, -C(O)R¹⁵ and -C(O)OR¹⁵;

R³ is hydrogen, halo or $-X^3R^{13}$;

X³ is a direct bond, $-\text{CH}_2=\text{CH}_2-$, $-\text{O}-$, $-\text{NH}-$, $-\text{N}(\text{C}_{1-6}\text{alkyl})-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$, $-\text{OC}(\text{O})-$, $-\text{NHC}(\text{O})-$, $-\text{N}(\text{C}_{1-6}\text{alkyl})\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{NH}-$ or $-\text{C}(\text{O})\text{N}(\text{C}_{1-6}\text{alkyl})-$;

R¹³ is hydrogen, or a group selected from $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{3-6}\text{cycloalkenyl}$, aryl, aryl $\text{C}_{1-4}\text{alkyl}$, aryl $\text{C}_{2-4}\text{alkenyl}$, aryl $\text{C}_{2-4}\text{alkynyl}$, heterocyclyl, heterocyclyl $\text{C}_{1-4}\text{alkyl}$, heterocyclyl $\text{C}_{2-4}\text{alkenyl}$ and heterocyclyl $\text{C}_{2-4}\text{alkynyl}$ which group is optionally substituted by 1 or 2 substituents independently selected from $-\text{NR}^7\text{R}^8$, $-\text{C}(\text{O})\text{NR}^7\text{R}^8$, halo, hydroxy, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxy}$, hydroxy $\text{C}_{1-4}\text{alkyl}$, hydroxy $\text{C}_{1-4}\text{alkylcarbonyl}$, $\text{C}_{1-4}\text{alkylcarbonyl}$, amino $\text{C}_{1-4}\text{alkylcarbonyl}$, $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkylcarbonyl}$ and bis($\text{C}_{1-4}\text{alkyl}$)amino $\text{C}_{1-4}\text{alkylcarbonyl}$;
R⁷ and **R⁸** are independently selected from hydrogen, heterocyclyl, heterocyclyl $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkylheterocyclylC}_{1-4}\text{alkyl}$, $\text{C}_{1-6}\text{alkyl}$, hydroxy $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxyC}_{1-6}\text{alkyl}$, $\text{C}_{3-6}\text{cycloalkyl}$, $\text{C}_{3-6}\text{cycloalkylC}_{1-4}\text{alkyl}$, hydroxy $\text{C}_{3-6}\text{cycloalkyl}$, hydroxy $\text{C}_{1-4}\text{alkylC}_{3-6}\text{cycloalkyl}$, hydroxy $\text{C}_{1-4}\text{alkylC}_{3-6}\text{cycloalkylC}_{1-4}\text{alkyl}$, hydroxy $\text{C}_{3-6}\text{cycloalkylC}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxyC}_{3-6}\text{cycloalkyl}$, $\text{C}_{1-4}\text{alkoxyC}_{3-6}\text{cycloalkylC}_{1-4}\text{alkyl}$, halo $\text{C}_{1-6}\text{alkyl}$, halo $\text{C}_{3-6}\text{cycloalkyl}$, halo $\text{C}_{3-6}\text{cycloalkylC}_{1-4}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$, $\text{C}_{2-6}\text{alkynyl}$, cyano $\text{C}_{1-4}\text{alkyl}$, amino $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{1-4}\text{alkylaminoC}_{1-6}\text{alkyl}$, bis($\text{C}_{1-4}\text{alkyl}$)amino $\text{C}_{1-6}\text{alkyl}$, hydroxy $\text{C}_{1-4}\text{alkoxyC}_{1-4}\text{alkyl}$, hydroxy $\text{C}_{1-4}\text{alkylcarbonyl}$, $\text{C}_{1-4}\text{alkylcarbonyl}$, amino $\text{C}_{1-4}\text{alkylcarbonyl}$, $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkylcarbonyl}$ and bis($\text{C}_{1-4}\text{alkyl}$)amino $\text{C}_{1-4}\text{alkylcarbonyl}$;

or **R⁷** and **R⁸** together with the nitrogen to which they are attached form a heterocyclic ring which ring is monocyclic or bicyclic and comprises 4 to 7 ring atoms of which one is nitrogen and of which another is optionally selected from N, NH, O, S, SO and SO_2 , and which ring is optionally substituted on carbon or nitrogen by 1 or 2 substituents independently selected from $\text{C}_{1-4}\text{alkyl}$, hydroxy, $\text{C}_{1-4}\text{alkoxy}$, hydroxy $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxyC}_{1-4}\text{alkyl}$, hydroxy $\text{C}_{1-4}\text{alkoxyC}_{1-4}\text{alkyl}$, $\text{C}_{1-4}\text{alkoxyC}_{1-4}\text{alkoxy}$, hydroxy $\text{C}_{1-4}\text{alkylcarbonyl}$, $\text{C}_{1-4}\text{alkylcarbonyl}$, amino $\text{C}_{1-4}\text{alkylcarbonyl}$, $\text{C}_{1-4}\text{alkylaminoC}_{1-4}\text{alkylcarbonyl}$ and bis($\text{C}_{1-4}\text{alkyl}$)amino $\text{C}_{1-4}\text{alkylcarbonyl}$, and where a ring $-\text{CH}_2-$ is optionally replaced with $-\text{C}(\text{O})-$;

R⁴ is selected from hydrogen, halo or $-X^4R^{14}$;

X⁴ is a direct bond, $-\text{O}-$, $-\text{NH}-$ or $-\text{N}(\text{C}_{1-6}\text{alkyl})-$;

R¹⁴ is selected from hydrogen, $\text{C}_{1-6}\text{alkyl}$, $\text{C}_{2-6}\text{alkenyl}$ and $\text{C}_{2-6}\text{alkynyl}$;

R⁵ is aryl or heteroaryl optionally substituted by 1, 2 or 3 substituents independently selected from halo, hydroxy, cyano, nitro, amino, $\text{C}_{1-4}\text{alkylamino}$, bis($\text{C}_{1-4}\text{alkyl}$)amino, $\text{C}_{1-4}\text{alkyl}$, $\text{C}_{2-4}\text{alkenyl}$, $\text{C}_{2-4}\text{alkynyl}$, $\text{C}_{1-4}\text{alkoxy}$, $-\text{C}(\text{O})\text{NHR}^{17}$, $-\text{NHC}(\text{O})\text{R}^{18}$, $-\text{SR}^{17}$, $-\text{S}(\text{O})\text{R}^{17}$ and $-\text{S}(\text{O})\text{OR}^{17}$;

R⁹, R¹⁰, R¹⁵ and R¹⁶ are independently selected from hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄alkyl, hydroxyC₁₋₆alkyl, haloC₁₋₆alkyl, aminoC₁₋₆alkyl, C₁₋₄alkylaminoC₁₋₆alkyl and bis(C₁₋₄alkyl)aminoC₁₋₆alkyl;

or **R⁹ and R¹⁰** together with the nitrogen to which they are attached form a heterocyclic ring which ring is monocyclic or bicyclic and comprises 4 to 7 ring atoms of which one is nitrogen and of which another is optionally selected from N, NH, O, S, SO and SO₂, and which ring is optionally substituted on carbon or nitrogen by 1 or 2 substituents independently selected from C₁₋₄alkyl, hydroxy, C₁₋₄alkoxy, hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, hydroxyC₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkoxy, hydroxyC₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl, aminoC₁₋₄alkylcarbonyl, C₁₋₄alkylaminoC₁₋₄alkylcarbonyl and bis(C₁₋₄alkyl)aminoC₁₋₄alkylcarbonyl, and where a ring -CH₂- is optionally replaced with -C(O)-;

R¹⁷ and R¹⁸ are independently selected from hydrogen, C₁₋₄alkyl, C₃₋₆cycloalkyl, C₂₋₄alkenyl and C₂₋₄alkynyl.

2. (currently amended) A compound according to claim 1 or a salt[;] or ester [~~or prodrug~~] thereof wherein X is NH.

3. (currently amended) A compound according to claim 1 or a salt[;] or ester [~~or prodrug~~] thereof wherein R⁴ is hydrogen.

4. (currently amended) A compound according to claim 1 or a salt[;] or ester [~~or prodrug~~] thereof wherein R⁵ is aryl optionally substituted by 1 or 2 halo.


5. (currently amended) A compound according to claim 1 or a salt[;] or ester [~~or prodrug~~] thereof wherein R¹ is hydrogen or -OR¹¹ and R¹¹ is hydrogen, heterocyclyl selected from piperidinyl or pyrrolidinyl or C₁₋₄alkyl which C₁₋₄alkyl is optionally substituted by hydroxy, C₁₋₄alkoxy, amino, C₁₋₄alkylamino or bis(C₁₋₄alkyl)amino.

6. (currently amended) A compound according to claim 1 or a salt[;] or ester [~~or prodrug~~] thereof wherein R² is hydrogen or -OR¹² and R¹² is hydrogen, C₁₋₄alkyl, heterocyclyl or heterocyclylC₁₋₄alkyl.

7. (currently amended) A compound according to claim 1 or a salt^[7] or ester ~~[or prodrug]~~ thereof wherein R^3 is $-X^3R^{13}$, X^3 is $-\text{CH}_2=\text{CH}_2-$, $-\text{O}-$ or $-\text{NH}-$, and R^{13} is C_{1-6} alkyl substituted by $-\text{NR}^7\text{R}^8$, heterocyclyl or halo.

8. (currently amended) A compound according to claim 7 or a salt^[7] or ester ~~[or prodrug]~~ thereof wherein R^7 and R^8 are independently selected from hydrogen, heterocyclyl, C_{1-6} alkyl, hydroxy C_{1-6} alkyl, hydroxy C_{1-4} alkyl C_{3-6} cycloalkyl, C_{1-4} alkoxy C_{1-4} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-4} alkyl, halo C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, cyano C_{1-4} alkyl and bis(C_{1-4} alkyl)amino C_{1-6} alkyl; or R^7 and R^8 together with the nitrogen to which they are attached form a heterocyclic ring which ring comprises 4 to 7 ring atoms of which one is nitrogen and of which another is optionally NH or O and which ring is optionally substituted on carbon or nitrogen by a group selected from C_{1-4} alkyl, hydroxy, hydroxy C_{1-4} alkyl and hydroxy C_{1-4} alkoxy C_{1-4} alkyl, and where a ring $-\text{CH}_2-$ is optionally replaced with $-\text{C}(\text{O})-$.

9. (original) A compound of formula (IA)



or a salt or ester thereof

where X , X^1 , X^2 , X^3 , R^4 and R^5 are as defined in relation to formula (I) in claim 1 and

$R^{1'}$ is hydrogen, halo, or $-\text{X}^1\text{R}^{11'}$;

$R^{11'}$ is hydrogen, phosphonooxy or a group selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, heterocyclyl, heterocyclyl C_{1-4} alkyl, heterocyclyl C_{2-4} alkenyl and heterocyclyl C_{2-4} alkynyl which group is optionally substituted by 1 or 2 substituents independently selected from halo, hydroxy, phosphonooxy, C_{1-4} alkoxy, hydroxy C_{1-4} alkyl, phosphonooxy C_{1-4} alkyl, $-\text{NR}^9\text{R}^{10'}$, $-\text{C}(\text{O})\text{R}^9$, $-\text{C}(\text{O})\text{NR}^9\text{R}^{10'}$ and $-\text{C}(\text{O})\text{OR}^9$;

$R^{2'}$ is hydrogen, halo, nitro, cyano or $-\text{X}^2\text{R}^{12'}$;

$R^{12'}$ is hydrogen, phosphonooxy or a group selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkenyl, aryl, aryl C_{1-4} alkyl, aryl C_{2-4} alkenyl, aryl C_{2-4} alkynyl, heterocyclyl,

heterocyclylC₁₋₄alkyl, heterocyclylC₂₋₄alkenyl and heterocyclylC₂₋₄alkynyl, which group is optionally substituted by 1, 2 or 3 substituents independently selected from halo, hydroxy, phosphonooxy, C₁₋₄alkyl, C₁₋₄alkoxy, -NR^{15'}R^{16'}, -NHC(O)NR^{15'}R^{16'}, -C(O)R^{15'} and -C(O)OR^{15'}; R^{3'} is hydrogen, halo or -X³R^{13'};

R^{13'} is hydrogen, phosphonooxy or a group selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkenyl, aryl, arylC₁₋₄alkyl, arylC₂₋₄alkenyl, arylC₂₋₄alkynyl, heterocyclyl, heterocyclylC₁₋₄alkyl, heterocyclylC₂₋₄alkenyl and heterocyclylC₂₋₄alkynyl which group is optionally substituted by 1 or 2 substituents independently selected from -NR^{7'}R^{8'}, -C(O)NR^{7'}R^{8'}, halo, hydroxy, phosphonooxy, C₁₋₄alkyl, C₁₋₄alkoxy, hydroxyC₁₋₄alkyl, phosphonooxyC₁₋₄alkyl, hydroxyC₁₋₄alkylcarbonyl, phosphonooxyC₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl, aminoC₁₋₄alkylcarbonyl, C₁₋₄alkylaminoC₁₋₄alkylcarbonyl and bis(C₁₋₄alkyl)aminoC₁₋₄alkylcarbonyl; R^{7'} and R^{8'} are independently selected from hydrogen, heterocyclyl, heterocyclylC₁₋₄alkyl, C₁₋₄alkylheterocyclylC₁₋₄alkyl, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, phosphonooxyC₁₋₆alkyl, C₁₋₄alkoxyC₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄alkyl, hydroxyC₃₋₆cycloalkyl, phosphonooxyC₃₋₆cycloalkyl, hydroxyC₁₋₄alkylC₃₋₆cycloalkyl, phosphonooxyC₁₋₄alkylC₃₋₆cycloalkyl, hydroxyC₃₋₆cycloalkylC₁₋₄alkyl, phosphonooxyC₃₋₆cycloalkylC₁₋₄alkyl, hydroxyC₁₋₄alkylC₃₋₆cycloalkylC₁₋₄alkyl, phosphonooxyC₁₋₄alkylC₃₋₆cycloalkylC₁₋₄alkyl, C₁₋₄alkoxyC₃₋₆cycloalkyl, C₁₋₄alkoxyC₃₋₆cycloalkylC₁₋₄alkyl, haloC₁₋₆alkyl, haloC₃₋₆cycloalkyl, haloC₃₋₆cycloalkylC₁₋₄alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, cyanoC₁₋₄alkyl, aminoC₁₋₆alkyl, C₁₋₄alkylaminoC₁₋₆alkyl, bis(C₁₋₄alkyl)aminoC₁₋₆alkyl, hydroxyC₁₋₄alkoxyC₁₋₄alkyl, phosphonooxyC₁₋₄alkoxyC₁₋₄alkyl, hydroxyC₁₋₄alkylcarbonyl, phosphonooxyC₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl, aminoC₁₋₄alkylcarbonyl, C₁₋₄alkylaminoC₁₋₄alkylcarbonyl and bis(C₁₋₄alkyl)aminoC₁₋₄alkylcarbonyl; or R^{7'} and R^{8'} together with the nitrogen to which they are attached form a heterocyclic ring which ring is monocyclic or bicyclic and comprises 4 to 7 ring atoms of which one is nitrogen and of which another is optionally selected from N, NH, O, S, SO and SO₂, and which ring is optionally substituted on carbon or nitrogen by 1 or 2 substituents independently selected from C₁₋₄alkyl, hydroxy, phosphonooxy, C₁₋₄alkoxy, hydroxyC₁₋₄alkyl, phosphonooxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, hydroxyC₁₋₄alkoxyC₁₋₄alkyl, phosphonooxyC₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkoxy, hydroxyC₁₋₄alkylcarbonyl, phosphonooxyC₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl, aminoC₁₋₄alkylcarbonyl, C₁₋₄alkylaminoC₁₋₄alkylcarbonyl and bis(C₁₋₄alkyl)aminoC₁₋₄alkylcarbonyl, and where a ring -CH₂- is optionally replaced with -C(O)-;

R^{9'}, **R^{10'}**, **R^{15'}** and **R^{16'}** are independently selected from hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₄alkyl, hydroxyC₁₋₆alkyl, phosphonooxyC₁₋₆alkyl, haloC₁₋₆alkyl, aminoC₁₋₆alkyl, C₁₋₄alkylaminoC₁₋₆alkyl and bis(C₁₋₄alkyl)aminoC₁₋₆alkyl; or **R^{9'}** and **R^{10'}** together with the nitrogen to which they are attached form a heterocyclic ring which ring is monocyclic or bicyclic and comprises 4 to 7 ring atoms of which one is nitrogen and of which another is optionally selected from N, NH, O, S, SO and SO₂, and which ring is optionally substituted on carbon or nitrogen by 1 or 2 substituents independently selected from C₁₋₄alkyl, hydroxy, phosphonooxy, C₁₋₄alkoxy, hydroxyC₁₋₄alkyl, phosphonooxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, hydroxyC₁₋₄alkoxyC₁₋₄alkyl, phosphonooxyC₁₋₄alkoxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkoxy, hydroxyC₁₋₄alkylcarbonyl, phosphonooxyC₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyl, aminoC₁₋₄alkylcarbonyl, C₁₋₄alkylaminoC₁₋₄alkylcarbonyl and bis(C₁₋₄alkyl)aminoC₁₋₄alkylcarbonyl, and where a ring -CH₂- is optionally replaced with -C(O)-; provided that a compound of formula (IA) contains at least one phosphonooxy group.

10. (original) A compound according to claim 9 or a salt or ester thereof wherein the compound or salt or ester thereof contains only one phosphonooxy group.

11. (original) A compound according to claim 9 or a salt or ester thereof wherein X is NH.

12. (original) A compound according to claim 9 or a salt or ester thereof wherein R⁴ is hydrogen.


13. (original) A compound according to claim 9 or a salt or ester thereof wherein R⁵ is aryl optionally substituted by 1 or 2 halo.

14. (currently amended) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt[,]or ester [~~or prodrug~~] thereof, in association with a pharmaceutically acceptable diluent or carrier.


15-17. (previously cancelled)

18. (currently amended) A method of treating a human suffering from [~~a hyperproliferative disease such as~~] breast or colorectal cancer comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt[,]or ester [~~or prodrug~~] thereof.

19. (currently amended) A process for the preparation of a compound of formula (I) as defined in claim 1 or a salt[,]or ester [~~or prodrug~~] thereof, which process comprises reacting a compound of formula (II) wherein R¹, R², R³ and R⁴ are as defined in claim 1



where L is a suitable leaving group with a compound of formula (III) wherein R⁵ and X are as defined in claim 1



in the presence of hydrochloric acid in dioxane under an inert atmosphere,
and thereafter if necessary:

- [i] ~~converting a compound of the formula (I) into another compound of the formula (I); and/or~~
- [i]i) removing any protecting groups; and/or
- [i]ii) forming a salt[,]or ester [~~or prodrug~~] thereof.

20. (original) A process for the preparation of a compound of formula (IA) as defined in claim 9 or a salt or ester thereof, which process comprises phosphorylation of a suitable compound of formula (I) followed by deprotection of the phosphate group.

21. (previously presented) A pharmaceutical composition comprising a compound of formula (IA) as defined in claim 9 or a pharmaceutically acceptable salt or ester thereof in association with a pharmaceutically acceptable diluent or carrier.

22. (currently amended) A method of treating a human suffering from ~~[a hyperproliferative disease such as]~~ breast or colorectal cancer comprising the steps of administering to a person in need thereof a therapeutically effective amount of a compound of formula (IA) as claimed in claim 9 or a pharmaceutically acceptable salt or ester thereof.

23. (previously presented) A compound selected from any one of:

2-(4-[[7-(3-chloropropoxy)-6-methoxyquinazolin-4-yl]amino]-1*H*-1,2,3-triazol-1-yl)-*N*-(3-fluorophenyl)acetamide;

2-(4-[[7-(3-chloropropoxy)quinazolin-4-yl]amino]-1*H*-1,2,3-triazol-1-yl)-*N*-(3-fluorophenyl)acetamide;

(4-[[7-(3-chloropropoxy)quinazolin-4-yl]amino]-1*H*-1,2,3-triazol-1-yl)-*N*-(2,3-difluorophenyl)acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[(2-hydroxyethyl)(propyl)amino]propoxy}-6-methoxyquinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[(2*S*)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy}-6-methoxyquinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[(2-hydroxyethyl)(propyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[(2*S*)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(3-fluorophenyl)-2-(4-[[7-(3-morpholin-4-yl)propoxy]quinazolin-4-yl]amino)-1*H*-1,2,3-triazol-1-yl)acetamide;

N-(3-fluorophenyl)-2-(4-[[7-(3-piperidin-1-yl)propoxy]quinazolin-4-yl]amino)-1*H*-1,2,3-triazol-1-yl)acetamide;

N-(3-fluorophenyl)-2-(4-[[7-(3-pyrrolidin-1-yl)propoxy]quinazolin-4-yl]amino)-1*H*-1,2,3-triazol-1-yl)acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

2-[4-((7-{3-(cyclopropylamino)propoxy}quinazolin-4-yl)amino)-1*H*-1,2,3-triazol-1-yl]-*N*-(3-fluorophenyl)acetamide;

2-{4-[(7-{3-[(2-(dimethylamino)ethyl)(methyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl]-*N*-(3-fluorophenyl)acetamide;

N-(3-fluorophenyl)-2-[4-((7-{3-(4-methylpiperazin-1-yl)propoxy}quinazolin-4-yl)amino)-1*H*-1,2,3-triazol-1-yl]acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[(2*R*)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(3-fluorophenyl)-2-[4-({7-[3-(4-hydroxypiperidin-1-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl]acetamide;

2-{4-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}-*N*-(3-fluorophenyl)acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(3-fluorophenyl)-2-(4-{[7-(3-piperazin-1-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl)acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[4-(2-hydroxyethyl)piperidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[4-(hydroxymethyl)piperidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(3-fluorophenyl)-2-{4-[(7-{3-[(2-hydroxyethyl)(isopropyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

2-{4-[(7-{3-[cyclopropyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}-*N*-(3-fluorophenyl)acetamide;

N-(2,3-difluorophenyl)-2-(4-{[7-(3-morpholin-4-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl)acetamide;

N-(2,3-difluorophenyl)-2-(4-{[7-(3-piperidin-1-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl)acetamide;

N-(2,3-difluorophenyl)-2-(4-{[7-(3-pyrrolidin-1-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl)acetamide;

N-(2,3-difluorophenyl)-2-{4-[(7-{3-[(2-hydroxy-1,1-dimethylethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

2-[4-({7-[3-(cyclopropylamino)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl]-*N*-(2,3-difluorophenyl)acetamide;

N-(2,3-difluorophenyl)-2-{4-[(7-{3-[[2-(dimethylamino)ethyl](methyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(2,3-difluorophenyl)-2-[4-({7-[3-(4-methylpiperazin-1-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl]acetamide;

N-(2,3-difluorophenyl)-2-{4-[(7-{3-[(2*R*)-2-(hydroxymethyl)pyrrolidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(2,3-difluorophenyl)-2-[4-({7-[3-(4-hydroxypiperidin-1-yl)propoxy]quinazolin-4-yl}amino)-1*H*-1,2,3-triazol-1-yl]acetamide;

N-(2,3-difluorophenyl)-2-{4-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(2,3-difluorophenyl)-2-{4-[(7-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(2,3-difluorophenyl)-2-(4-{[7-(3-piperazin-1-ylpropoxy)quinazolin-4-yl]amino}-1*H*-1,2,3-triazol-1-yl)acetamide;

N-(2,3-difluorophenyl)-2-{4-[(7-{3-[4-(2-hydroxyethyl)piperidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(2,3-difluorophenyl)-2-{4-[(7-{3-[4-(hydroxymethyl)piperidin-1-yl]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide;

N-(2,3-difluorophenyl)-2-{4-[(7-{3-[(2-hydroxyethyl)(isopropyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}acetamide; and

2-{4-[(7-{3-[cyclopropyl(2-hydroxyethyl)amino]propoxy}quinazolin-4-yl)amino]-1*H*-1,2,3-triazol-1-yl}-*N*-(2,3-difluorophenyl)acetamide;

or a salt, ester or prodrug thereof.